Rumgay H, Arnold M, Ferlay J, Lesi O, Cabasag CJ, Vignat J, et al. Global burden of primary liver cancer in 2020 and predictions to 2040. J Hepatol. 2022;77:1598–606.
Google ScholarÂ
Oura K, Morishita A, Hamaya S, Fujita K, Masaki T. The roles of epigenetic regulation and the tumor microenvironment in the mechanism of resistance to systemic therapy in hepatocellular carcinoma. Int J Mol Sci. 2023;24:2805.
Google ScholarÂ
Lin J, Rao D, Zhang M, Gao Q. Metabolic reprogramming in the tumor microenvironment of liver cancer. J Hematol Oncol. 2024;17:6.
Google ScholarÂ
Park S, Hall MN. Metabolic reprogramming in hepatocellular carcinoma: mechanisms and therapeutic implications. Exp Mol Med. 2025;57:515–23.
Google ScholarÂ
Nava GM, Madrigal Perez LA. Metabolic profile of the Warburg effect as a tool for molecular prognosis and diagnosis of cancer. Expert Rev Mol Diagn. 2022;22:439–47.
Google ScholarÂ
Ji Y, Xu Z, Tang L, Huang T, Mu X, Ni C, et al. O-GlcNAcylation of YBX1 drives a glycolysis-histone lactylation feedback loop in hepatocellular carcinoma. Cancer Lett. 2025;631:217957.
Google ScholarÂ
Liu H, Wang S, Wang J, Guo X, Song Y, Fu K, et al. Energy metabolism in health and diseases. Signal Transduct Target Ther. 2025;10:69.
Google ScholarÂ
Li BH, Cao YJ, Meng G, Qian LY, Xu TC, Yan C, et al. Targeting glutaminase 1 attenuates stemness properties in hepatocellular carcinoma by increasing reactive oxygen species and suppressing Wnt/beta-catenin pathway. Ebiomedicine. 2019;39:239–54.
Google ScholarÂ
Zou WX, Han ZT, Wang ZH, Liu Q. Targeting glutamine metabolism as a potential target for cancer treatment. J Exp Clin Canc Res. 2025;44:180.
Google ScholarÂ
Momcilovic M, Bailey ST, Lee JT, Fishbein MC, Braas D, Go J, et al. The GSK3 signaling axis regulates adaptive glutamine metabolism in lung squamous cell carcinoma. Cancer Cell. 2018;33:905–21.e5.
Google ScholarÂ
Elgogary A, Xu Q, Poore B, Alt J, Zimmermann SC, Zhao L, et al. Combination therapy with BPTES nanoparticles and metformin targets the metabolic heterogeneity of pancreatic cancer. Proc Natl Acad Sci USA. 2016;113:E5328–36.
Google ScholarÂ
Yang S, Pang L, Dai W, Wu S, Kong J. Role of forkhead box O proteins in hepatocellular carcinoma biology and progression (Review). Front Oncol. 2021;11:667730.
Google ScholarÂ
Tsuji T, Maeda Y, Kita K, Murakami K, Oshima H. FOXO3 is a latent tumor suppressor for FOXO3-positive and cytoplasmic-type gastric cancer cells. Oncogene. 2021;40:3072–86.
Google ScholarÂ
Yang L, Deng WL, Zhao BG, Xu Y, Wang XW, Fang Y, et al. FOXO3-induced lncRNA LOC554202 contributes to hepatocellular carcinoma progression via the miR-485-5p/BSG axis. Cancer Gene Ther. 2022;29:326–40.
Google ScholarÂ
Xu X, Li J, Sun X, Guo Y, Shen L. Tumor suppressor NDRG2 inhibits glycolysis and glutaminolysis in colorectal cancer cells by repressing c-Myc expression. Oncotarget. 2015;6:26161–76.
Google ScholarÂ
Cao G, Lin M, Gu W, Su Z, Duan Y, Song W, et al. The rules and regulatory mechanisms of FOXO3 on inflammation, metabolism, cell death and aging in hosts. Life Sci. 2023;328:121877.
Google ScholarÂ
Masui K, Tanaka K, Akhavan D, Babic I, Gini B, Matsutani T, et al. MTOR complex 2 controls glycolytic metabolism in glioblastoma through FoxO acetylation and upregulation of c-Myc. Cell Metab. 2013;18:726–39.
Google ScholarÂ
Yeo H, Lyssiotis CA, Zhang Y, Ying H, Asara JM, Cantley LC, et al. FoxO3 coordinates metabolic pathways to maintain redox balance in neural stem cells. Embo J. 2013;32:2589–602.
Google ScholarÂ
Sun R, Xu Y, Zhang H, Yang Q, Wang K, Shi Y, et al. Mechanistic modeling of gene regulation and metabolism identifies potential targets for hepatocellular carcinoma. Front Genet. 2020;11:595242.
Google ScholarÂ
Jung O, Baek M-j, Wooldrik C, Johnson KR, Fisher KW, Lou J, et al. Nuclear phosphoinositide signaling promotes YAP/TAZ-TEAD transcriptional activity in breast cancer. EMBO J. 2024;43:1740–69.
Google ScholarÂ
Chen R, Zhu S, Fan X-G, Wang H, Lotze MT, Zeh HJ, et al. High mobility group protein B1 controls liver cancer initiation through yes-associated protein -dependent aerobic glycolysis. Hepatology. 2018;67:1823–41.
Google ScholarÂ
Edwards DN, Ngwa VM, Wang S, Shiuan E, Brantley-Sieders DM, Kim LC, et al. The receptor tyrosine kinase EphA2 promotes glutamine metabolism in tumors by activating the transcriptional coactivators YAP and TAZ. Sci Signal. 2017;10:eaan4667.
Google ScholarÂ
Deepika N, Prasad NR, Radhiga T. Auranofin sensitizes breast cancer cells to paclitaxel mediated cell death via regulating FOXO3/Nrf2/Keap1 signaling pathway. Cell Biochem Funct. 2024;42:e3903.
Google ScholarÂ
Qian K, Sun L, Zhou G, Ge H, Meng Y, Li J, et al. Trifluoperazine as an alternative strategy for the inhibition of tumor growth of colorectal cancer. J Cell Biochem. 2019;120:15756–65.
Google ScholarÂ
Gyorffy B. Integrated analysis of public datasets for the discovery and validation of survival-associated genes in solid tumors. Innovation. 2024;5:100625.
Google ScholarÂ
Li C, Zhao Y, Yang D, Yu Y, Guo H, Zhao Z, et al. Inhibitory effects of kaempferol on the invasion of human breast carcinoma cells by downregulating the expression and activity of matrix metalloproteinase-9. Biochem Cell Biol. 2015;93:16–27.
Google ScholarÂ
Li C, Yang D, Zhao Y, Qiu Y, Cao X, Yu Y, et al. Inhibitory effects of isorhamnetin on the invasion of human breast carcinoma cells by downregulating the expression and activity of matrix metalloproteinase-2/9. Nutr Cancer. 2015;67:1191–200.
Google ScholarÂ
Li C, Lu N, Qi Q, Li F, Ling Y, Chen Y, et al. Gambogic acid inhibits tumor cell adhesion by suppressing integrin beta1 and membrane lipid rafts-associated integrin signaling pathway. Biochem Pharm. 2011;82:1873–83.
Google ScholarÂ
Li CL, Li J, Gong SY, Huang M, Li R, Xiong GX, et al. Targeting the ILK/YAP axis by LFG-500 blocks epithelial-mesenchymal transition and metastasis. Acta Pharm Sin. 2021;42:1847–59.
Google ScholarÂ
Wang L, Zhang X, Lin ZB, Yang PJ, Xu H, Duan JL, et al. Tripartite motif 16 ameliorates nonalcoholic steatohepatitis by promoting the degradation of phospho-TAK1. Cell Metab. 2021;33:1372–88.
Google ScholarÂ
Schreiber S, Daum P, Danzer H, Hauke M, Jack HM, Wittmann J. Identification of miR-128 target mRNAs that are expressed in B cells using a modified dual luciferase vector. Biomolecules. 2023;13:1517.
Google ScholarÂ
Ji SY, Feng L, Fu ZL, Wu GH, Wu YC, Lin YP, et al. Pharmaco-proteogenomic characterization of liver cancer organoids for precision oncology. Sci Transl Med. 2023;15:eadg3358.
Google ScholarÂ
Flores-Garcia LC, Garcia-Castillo V, Perez-Toledo E, Trujano-Camacho S, Millan-Catalan O, Perez-Yepez EA, et al. HOTAIR participation in glycolysis and glutaminolysis through lactate and glutamate production in colorectal cancer. Cells. 2025;14:388.
Google ScholarÂ
Kalyanaraman B. Teaching the basics of cancer metabolism: developing antitumor strategies by exploiting the differences between normal and cancer cell metabolism. Redox Biol. 2017;12:833–42.
Google ScholarÂ
Wang L, Li JJ, Guo LY, Li P, Zhao Z, Zhou H, et al. Molecular link between glucose and glutamine consumption in cancer cells mediated by CtBP and SIRT4. Oncogenesis. 2018;7:26.
Google ScholarÂ
Ebrahimnezhad M, Valizadeh A, Majidinia M, Tabnak P, Yousefi B. Unveiling the potential of FOXO3 in lung cancer: From molecular insights to therapeutic prospects. Biomed Pharmacother. 2024;176:116833.
Google ScholarÂ
Guan S, Lin Q, Huang P, Lin K, Duan S. Identification of a novel FOXO3‑associated prognostic model in hepatocellular carcinoma. Oncol Lett. 2025;29:230.
Google ScholarÂ
Wang P, Mao B, Luo W, Wei B, Jiang W, Liu D, et al. The alteration of Hippo/YAP signaling in the development of hypertrophic cardiomyopathy. Basic Res Cardiol. 2014;109:435.
Google ScholarÂ
Shi H, Zou Y, Zhong W, Li Z, Wang X, Yin Y, et al. Complex roles of Hippo-YAP/TAZ signaling in hepatocellular carcinoma. J Cancer Res Clin Oncol. 2023;149:15311–22.
Google ScholarÂ
Wang Y, Li J, Gao Y, Luo Y, Luo H, Wang L, et al. Hippo kinases regulate cell junctions to inhibit tumor metastasis in response to oxidative stress. Redox Biol. 2019;26:101233.
Google ScholarÂ
Kurlishchuk Y, Cindric Vranesic A, Jessen M, Kipping A, Ritter C, Kim K, et al. A non-canonical repressor function of JUN restrains YAP activity and liver cancer growth. EMBO J. 2024;43:4578–603.
Google ScholarÂ
Essers MAG, de Vries-Smits LMM, Barker N, Polderman PE, Burgering BMT, Korswagen HC. Functional interaction between β-catenin and FOXO in oxidative stress signaling. Science. 2005;308:1181–4.
Google ScholarÂ
Tenbaum SP, Ordóñez-Morán P, Puig I, Chicote I, Arqués O, Landolfi S, et al. β-catenin confers resistance to PI3K and AKT inhibitors and subverts FOXO3a to promote metastasis in colon cancer. Nat Med. 2012;18:892–901.
Google ScholarÂ
Li J, Du W, Maynard S, Andreassen PR, Pang QS. Oxidative stress-specific interaction between FANCD2 and FOXO3a. Blood. 2010;115:1545–8.
Google ScholarÂ
Mahmud Z, Gomes AR, Lee HJ, Aimjongjun S, Jiramongkol Y, Yao S, et al. EP300 and SIRT1/6 Co-regulate lapatinib sensitivity via modulating FOXO3-acetylation and activity in breast cancer. Cancers. 2019;11:1067.
Google ScholarÂ
Zhang L, Cai M, Gong Z, Zhang B, Li Y, Guan L, et al. Geminin facilitates FoxO3 deacetylation to promote breast cancer cell metastasis. J Clin Invest. 2017;127:2159–75.
Google ScholarÂ
Eijkelenboom A, Mokry M, Smits LM, Nieuwenhuis EE, Burgering BM. FOXO3 selectively amplifies enhancer activity to establish target gene regulation. Cell Rep. 2013;5:1664–78.
Google ScholarÂ
Fu M, Hu Y, Lan T, Guan KL, Luo T, Luo M. The Hippo signalling pathway and its implications in human health and diseases. Signal Transduct Target Ther. 2022;7:376.
Google ScholarÂ
Reggiani F, Gobbi G, Ciarrocchi A, Sancisi V. YAP and TAZ are not identical twins. Trends Biochem Sci. 2021;46:154–68.
Google ScholarÂ
Liu F, Liao Z, Zhang Z. MYC in liver cancer: mechanisms and targeted therapy opportunities. Oncogene. 2023;42:3303–18.
Google ScholarÂ
Tian LY, Smit DJ, Jucker M. The role of PI3K/AKT/mTOR signaling in hepatocellular carcinoma metabolism. Int J Mol Sci. 2023;24:2652.
Google ScholarÂ
Zhang X, Camprecios G, Rimmele P, Liang R, Yalcin S, Mungamuri SK, et al. FOXO3-mTOR metabolic cooperation in the regulation of erythroid cell maturation and homeostasis. Am J Hematol. 2014;89:954–63.
Google ScholarÂ
Zhu J, Zhu H, Zhu Q, Xu SL, Xiao L, Zhang MY, et al. The roles of autophagy, ferroptosis and pyroptosis in the anti-ovarian cancer mechanism of harmine and their crosstalk. Sci Rep. 2024;14:6504.
Google ScholarÂ
Liu JC, Wang HY, Wan HZ, Yang J, Gao LK, Wang Z, et al. NEK6 dampens FOXO3 nuclear translocation to stabilize C-MYC and promotes subsequent de novo purine synthesis to support ovarian cancer chemoresistance. Cell Death Dis. 2024;15:661.
Google ScholarÂ
Park YY, Sohn BH, Johnson RL, Kang MH, Kim SB, Shim JJ, et al. Yes-associated protein 1 and transcriptional coactivator with PDZ-binding motif activate the mammalian target of rapamycin complex 1 pathway by regulating amino acid transporters in hepatocellular carcinoma. Hepatology. 2016;63:159–72.
Google ScholarÂ
Turato C, Cannito S, Simonato D, Villano G, Morello E, Terrin L, et al. SerpinB3 and Yap interplay increases Myc oncogenic activity. Sci Rep. 2015;5:17701.
Google ScholarÂ
Zhong S, Chen W, Wang B, Gao C, Liu X, Song Y, et al. Energy stress modulation of AMPK/FoxO3 signaling inhibits mitochondria-associated ferroptosis. Redox Biol. 2023;63:102760.
Google ScholarÂ
Ramis G, Villalonga-Planells R, Serra-Sitjar M, Brell M, Fernandez de Mattos S, Villalonga P. The tumor suppressor FOXO3a mediates the response to EGFR inhibition in glioblastoma cells. Cell Oncol. 2019;42:521–36.
Google ScholarÂ
Liu C, Zhao Y, Wang J, Yang Y, Zhang Y, Qu X, et al. FoxO3 reverses 5-fluorouracil resistance in human colorectal cancer cells by inhibiting the Nrf2/TR1 signaling pathway. Cancer Lett. 2020;470:29–42.
Google ScholarÂ
Pobbati AV, Hong W. A combat with the YAP/TAZ-TEAD oncoproteins for cancer therapy. Theranostics. 2020;10:3622–35.
Google ScholarÂ
